Tacrolimus Treatment for Post-COVID-19 Interstitial Lung Disease

Migiwa Ohgushi, Naruhiko Ogo, Toyoshi Yanagihara, Yukiko Harada, Kosuke Sumida, Ayaka Egashira, Tatsuma Asoh, Takashige Maeyama, Seiji Yoshizawa

Research output: Contribution to journalArticlepeer-review

7 Citations (Scopus)


With expansion of the COVID-19 pandemic, reports of post-COVID-19 interstitial lung disease (ILD) have been emerging. However, there are few reports regarding treatment. Some reports indicate that corticosteroids are effective for post-COVID-19 ILD, but the use of long-term corticosteroid carries risks of side effects. We administered tacrolimus to an elderly patient with post-COVID-19 ILD who suffered a respiratory failure relapse during steroid tapering. The respiratory status improved with tacrolimus in the post-acute phase, but pulmonary fibrosis progressed in the late phase. Tacrolimus may be effective for treating post-COVID-19 ILD in the post-acute phase, but it does not halt progression of pulmonary fibrosis.

Original languageEnglish
Pages (from-to)585-589
Number of pages5
JournalInternal Medicine
Issue number4
Publication statusPublished - 2022

All Science Journal Classification (ASJC) codes

  • Internal Medicine


Dive into the research topics of 'Tacrolimus Treatment for Post-COVID-19 Interstitial Lung Disease'. Together they form a unique fingerprint.

Cite this